Skin GraftMATRIGREFFENCT02090361
Efficacy of Collagen-elastin Dermal Substitute in the Treatment of Loss of Cutaneous Substances With Skin Grafts
A study testing skin graft in people with Skin Graft and Collagen -Elastin Matrix, run by University Hospital, Rouen at 4 sites in France.
Trial summary
In reconstructive surgery , most losses of cutaneous substance require the use of a thin skin graft . This technique allows epidermization of the defect by applying a thin layer of autologous epidermis. It does not reconstitute the injured skin. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Skin Graft, Collagen -Elastin Matrix
- What is being tested?
- skin graft
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 92 participants
- Where
- 4 sitesFrance
- Study dates
- 18 Jun 2014to 26 Feb 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Aged over 18
- Signed informed consent
- Patients with loss of cutaneous substance of at least 15 cm2
- Patient Without bone exposure, vascular, joint or tendon
- Eligibility for surgical treatment by skin graft
- Loss of substance trauma (avulsion, burns) or surgery (skin excision)
Who cannot join
- Patient with a chronic wound
- Wound superinfected
- Patient unable for local or general skin graft
- Patient with an old or a recent skin injury strictly contralateral to the graft site.
- Patient unable to consent
Trial locations and contacts
4 sites in 1 country.
France4 sites
CHU d'Amiens
Amiens
CHU de Caen
Caen
CHU de Lille
Lille
UH Rouen
Rouen, 76031
About this study
In reconstructive surgery , most losses of cutaneous substance require the use of a thin skin graft . This technique allows epidermization of the defect by applying a thin layer of autologous epidermis. It does not reconstitute the injured skin. Transplants cause retractile scars, adherent to the deep plan, that may require revision surgery . Since a decade , dermal matrices are mainly used in burned skin centers . The collagen -elastin matrix has the advantage to set up in the same operation that the skin graft and contain elastic fibers , two assets which improve the results of skin grafting.
Objective:
Read more
Evaluation of the clinical efficacy of the addition of a dermal matrix to skin graft on Skin Foldability, at day 360.
Methodology:
This is a multicenter randomized study (CHU Caen , Amiens, Rouen and Lille)
Conduct of the study :
The transplant will be performed according to the protocol defined between inter -region surgeons. The implementation of the dermal matrix will be in the same surgical technique as thin skin graft ( group 1 ) or the thin skin graft will be performed alone ( group 2) time .
Evaluation Criteria Main : Skin Foldability ( Uf ) assessed grafted site will be compared to the opposite side ungrafted evaluated at Day 360 . Quantitative data will be measured by a cutometer Skin Elasticity Meter 580 (Courage and Khazaba Electronic GmbH).
To achieve the main objective, it is planned to compare the ratio between Uf graft site and the opposite healthy site between two groups: skin + matrix graft , or skin graft only. Thus, the Wilcoxon test for independent samples will be used to settle bilateral formulation between the null hypothesis ( there is no difference between the two groups ) and the alternative hypothesis ( there is a difference between the two groups ) . In determining the overall risk of first species to 5% and the power of this test to detect the 90% expected under the alternative hypothesis difference should be the main criterion for evaluating at least 59 patients in each group so 118 patients total.
Prospect If the contribution of a dermal matrix in loss of skin substances improves skin pliability and reduces pain , functional and aesthetic sequelae grafts thin skin , the dermal matrix may be proposed as a complementary treatment in these indications.
- Conditions
- Skin Graft, Collagen -Elastin Matrix
- Being tested
- skin graft
- Keywords
- collagen -elastin matrix, skin graft, loss of cutaneous substance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
skin graftProcedure or surgery
Epidermization of the defect by applying a thin layer of autologous epidermis
| Study group | Role | What they receive |
|---|---|---|
| skin graft with dermal matrix | Experimental | Epidermization of the defect by applying a thin layer of autologous epidermis with addition of a dermal matrix Receives: Procedure: skin graft |
| skin graft - classic procedure | Placebo comparator | Epidermization of the defect by applying a thin layer of autologous epidermis |
What is being measured
The primary outcome is the main question the study is designed to answer.
Skin Foldability ( Uf )
Skin Foldability ( Uf ) will be assessed on grafted site compared to the opposite side ungrafted at day D360 . Quantitative data will be measured by a cutometer Skin Elasticity Meter 580 (Courage and Khazaba Electronic GmbH).
Measured: Day 360
Secondary outcomes (19)
Skin Foldability ( Uf )
Skin Foldability ( Uf ) will be assessed on grafted site compared to the opposite side ungrafted at day D180 . Quantitative data will be measured by a cutometer Skin Elasticity Meter 580 (Courage and Khazaba Electronic GmbH)
Measured: Day 180
Skin Foldability ( Uf )
Skin Foldability ( Uf ) will be assessed on grafted site compared to the opposite side ungrafted at day D90 . Quantitative data will be measured by a cutometer Skin Elasticity Meter 580 (Courage and Khazaba Electronic GmbH)
Measured: Day 90
Pain on the grafted site
Assessment of pain on the grafted site EVA at Day 7
Measured: D7
pain on the grafted site
Assessment of pain on the grafted site at Day 15
Measured: Day 15
pain on the grafted site
Assessment of pain at the grafted site EVA to D30
Measured: Day 30
pain on the grafted site
Assessment of pain at the grafted site EVA at D30
Measured: Day 90
pain on the grafted site
Assessment of pain at the grafted site EVA at Day 180
Measured: Day 180
pain on the grafted site
Assessment of pain at the grafted site EVA at Day 360
Measured: Day 360
tolerance of matriderm use
Occurrence within 360 days of a local complication requiring reoperation
Measured: Day 360
Area healed
Evaluation of the percentage of area healed at Day 7
Measured: Day 7
Area healed
Evaluation of the percentage of area healed at Day 15
Measured: Day 15
Area healed
Evaluation of the percentage of area healed at Day 30
Measured: Day 30
Assessment of functional effects
Assessment of functional effects of the scar on the patient 's daily activities defined at Day 30
Measured: Day 30
Assessment of functional effects
Assessment of functional effects of the scar on the patient 's daily activities defined at Day 90
Measured: Day 90
Assessment of functional effects
Assessment of functional effects of the scar on the patient 's daily activities defined at Day 180
Measured: Day 180
Assessment of functional effects
Assessment of functional effects of the scar on the patient 's daily activities defined at Day 360
Measured: Day 360
Aesthetic sequelae evaluation
Evaluation aesthetic sequelae by a committee of independent experts to study the photographs taken at day 90
Measured: Day 90
Aesthetic sequelae evaluation
Evaluation aesthetic sequelae by a committee of independent experts to study the photographs taken at day 180
Measured: Day 180
Aesthetic sequelae evaluation
Evaluation aesthetic sequelae by a committee of independent experts to study the photographs taken at day 360
Measured: Day 360
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Mar 2014 (estimated)
- Study start18 Jun 2014
- Primary completion26 Feb 2019
- Study completion26 Feb 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Skin GraftStudies of the same condition, open and under way.
- More trials run by University Hospital, RouenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Enrolment
- 92 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Rouen
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Isabelle AUQUIT-AUCKBUR, Pr, Principal investigator, UH Rouen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02090361
- Sponsor's protocol ID
- 2013/0008/HP
- Acronym
- MATRIGREFFE
- Status last verified
- Feb 2026
- First submitted
- 14 Mar 2014
- Last updated
- 13 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of Collagen-elastin Dermal Substitute in the Treatment of Loss of Cutaneous Substances With Skin Grafts
- ClinicalTrials.gov ID
- NCT02090361
- Acronym / sponsor ID
- MATRIGREFFE / 2013/0008/HP
- Conditions
- Skin Graft, Collagen -Elastin Matrix
- Keywords
- collagen -elastin matrix, skin graft, loss of cutaneous substance
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 92 participants (actual)
- Lead sponsor
- University Hospital, RouenUniversity, hospital or other
- Study start
- 18 Jun 2014 (actual)
- Primary completion
- 26 Feb 2019 (actual)
- Study completion
- 26 Feb 2019 (actual)
- First posted
- 18 Mar 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In reconstructive surgery , most losses of cutaneous substance require the use of a thin skin graft . This technique allows epidermization of the defect by applying a thin layer of autologous epidermis. It does not reconstitute the injured skin. Transplants cause retractile scars, adherent to the deep plan, that may require revision surgery . Since a decade , dermal matrices are mainly used in burned skin centers . The collagen -elastin matrix has the advantage to set up in the same operation that the skin graft and contain elastic fibers , two assets which improve the results of skin grafting.
Objective:
Evaluation of the clinical efficacy of the addition of a dermal matrix to skin graft on Skin Foldability, at day 360.
Methodology:
This is a multicenter randomized study (CHU Caen , Amiens, Rouen and Lille)
Conduct of the study :
The transplant will be performed according to the protocol defined between inter -region surgeons. The implementation of the dermal matrix will be in the same surgical technique as thin skin graft ( group 1 ) or the thin skin graft will be performed alone ( group 2) time .
Evaluation Criteria Main : Skin Foldability ( Uf ) assessed grafted site will be compared to the opposite side ungrafted evaluated at Day 360 . Quantitative data will be measured by a cutometer Skin Elasticity Meter 580 (Courage and Khazaba Electronic GmbH).
To achieve the main objective, it is planned to compare the ratio between Uf graft site and the opposite healthy site between two groups: skin + matrix graft , or skin graft only. Thus, the Wilcoxon test for independent samples will be used to settle bilateral formulation between the null hypothesis ( there is no difference between the two groups ) and the alternative hypothesis ( there is a difference between the two groups ) . In determining the overall risk of first species to 5% and the power of this test to detect the 90% expected under the alternative hypothesis difference should be the main criterion for evaluating at least 59 patients in each group so 118 patients total.
Prospect If the contribution of a dermal matrix in loss of skin substances improves skin pliability and reduces pain , functional and aesthetic sequelae grafts thin skin , the dermal matrix may be proposed as a complementary treatment in these indications.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| skin graft with dermal matrix | Experimental | Procedure: skin graftEpidermization of the defect by applying a thin layer of autologous epidermis with addition of a dermal matrix |
| skin graft - classic procedure | Placebo comparator | –Epidermization of the defect by applying a thin layer of autologous epidermis |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Aged over 18
- Signed informed consent
- Patients with loss of cutaneous substance of at least 15 cm2
- Patient Without bone exposure, vascular, joint or tendon
- Eligibility for surgical treatment by skin graft
Key exclusion criteria (5 listed)
- Patient with a chronic wound
- Wound superinfected
- Patient unable for local or general skin graft
- Patient with an old or a recent skin injury strictly contralateral to the graft site.
- Patient unable to consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| skin graftEpidermization of the defect by applying a thin layer of autologous epidermis | Procedure or surgery | skin graft with dermal matrix |
Primary outcome
Skin Foldability ( Uf )
Time frame: Day 360
Skin Foldability ( Uf ) will be assessed on grafted site compared to the opposite side ungrafted at day D360 . Quantitative data will be measured by a cutometer Skin Elasticity Meter 580 (Courage and Khazaba Electronic GmbH).
19 secondary outcomes
Skin Foldability ( Uf )
Time frame: Day 180
Skin Foldability ( Uf )
Time frame: Day 90
Pain on the grafted site
Time frame: D7
pain on the grafted site
Time frame: Day 15
pain on the grafted site
Time frame: Day 30
pain on the grafted site
Time frame: Day 90
pain on the grafted site
Time frame: Day 180
pain on the grafted site
Time frame: Day 360
tolerance of matriderm use
Time frame: Day 360
Area healed
Time frame: Day 7
Area healed
Time frame: Day 15
Area healed
Time frame: Day 30
Assessment of functional effects
Time frame: Day 30
Assessment of functional effects
Time frame: Day 90
Assessment of functional effects
Time frame: Day 180
Assessment of functional effects
Time frame: Day 360
Aesthetic sequelae evaluation
Time frame: Day 90
Aesthetic sequelae evaluation
Time frame: Day 180
Aesthetic sequelae evaluation
Time frame: Day 360
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Feb 2026.
Related trials for Skin Graft
Not yet recruiting
Safety Study of Microlyte DualGuard
Wound Closure, Wound Care
RecruitingPhase 1/2
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
Autoimmune Disorders, Systemic Sclerosis
Recruiting
Surgical Outcomes of Simple Interrupted Versus Running Epidermal Sutures in Full-thickness Skin Graft Placement
Skin Graft Scar
Active, not recruiting
Patient Reported Outcomes With UVA-1 Therapy for Treatment of Sclerosing Skin Diseases
Scleroderma, Systemic, Morphea
Not yet recruiting
Full-Thickness Skin Graft Sizing and Scar Quality
Graft Healing
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Isabelle AUQUIT-AUCKBUR, Pr principal investigator
UH Rouen
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing skin graft in people with Skin Graft and Collagen -Elastin Matrix, run by University Hospital, Rouen at 4 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Skin Foldability ( Uf ) (time frame: Day 360). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Feb 2026.